|Amino acid derivatives are substrates or non-transported inhibitors of the amino acid transporter PAT2 (slc36a2).|
|Jump to Full Text|
|PMID: 20691150 Owner: NLM Status: MEDLINE|
|The H(+)-coupled amino acid transporter PAT2 (SLC36A2) transports the amino acids proline, glycine, alanine and hydroxyproline. A physiological role played by PAT2 in amino acid reabsorption in the renal proximal tubule is demonstrated by mutations in SLC36A2 that lead to an iminoglycinuric phenotype (imino acid and glycine uria) in humans. A number of proline, GABA and tryptophan derivatives were examined to determine if they function either as transported substrates or non-transported inhibitors of PAT2. The compounds were investigated following heterologous expression of rat PAT2 in Xenopus laevis oocytes. PAT2 function was characterised by: radiotracer uptake and competition (cis-inhibition) studies; radiotracer efflux and trans-stimulation; and measurement of substrate-induced positive inward current by two-electrode voltage-clamp. In general, the proline derivatives appeared to be transported substrates and the relative ability to induce current flow was closely related to the inhibitory effects on PAT2-mediated l-[(3)H]proline uptake. In contrast, certain heterocyclic GABA derivatives (e.g. l-pipecolic acid) were translocated only slowly. Finally, the tryptophan derivatives inhibited PAT2 function but did not undergo transport. l-Proline uptake was inhibited by 5-hydroxy-l-tryptophan (IC(50) 1.6±0.4mM), α-methyl-d,l-tryptophan (3.5±1.5mM), l-tryptophan, 1-methyl-l-tryptophan and indole-3-propionic acid. Although neither 5-hydroxy-l-tryptophan nor α-methyl-d,l-tryptophan were able to elicit inward current in PAT2-expressing oocytes both reduced the current evoked by l-proline. 5-Hydroxy-l-tryptophan and α-methyl-d,l-tryptophan were unable to trans-stimulate l-proline efflux from PAT2-expressing oocytes, confirming that the two compounds act as non-transported blockers of PAT2. These two tryptophan derivatives should prove valuable experimental tools in future investigations of the physiological roles of PAT2.|
|Noel Edwards; Catriona M H Anderson; Kelly M Gatfield; Mark P Jevons; Vadivel Ganapathy; David T Thwaites|
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-08-04|
|Title: Biochimica et biophysica acta Volume: 1808 ISSN: 0006-3002 ISO Abbreviation: Biochim. Biophys. Acta Publication Date: 2011 Jan|
|Created Date: 2010-12-06 Completed Date: 2011-03-07 Revised Date: 2013-05-29|
Medline Journal Info:
|Nlm Unique ID: 0217513 Medline TA: Biochim Biophys Acta Country: Netherlands|
|Languages: eng Pagination: 260-70 Citation Subset: IM|
|Copyright © 2010 Elsevier B.V. All rights reserved.|
|Epithelial Research Group, Institute for Cell & Molecular Biosciences, Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.|
|APA/MLA Format Download EndNote Download BibTex|
Amino Acid Transport Systems, Neutral
Amino Acids / metabolism
Dose-Response Relationship, Drug
Electrophysiology / methods
Inhibitory Concentration 50
Oocytes / metabolism
Proline / chemistry
Symporters / chemistry*
Tryptophan / chemistry
Xenopus laevis / metabolism
gamma-Aminobutyric Acid / analogs & derivatives
|//Biotechnology and Biological Sciences Research Council; //Wellcome Trust|
|0/Amino Acid Transport Systems, Neutral; 0/Amino Acids; 0/Slc36a2 protein, rat; 0/Symporters; 147-85-3/Proline; 56-12-2/gamma-Aminobutyric Acid; 73-22-3/Tryptophan|
Journal ID (nlm-ta): Biochim Biophys Acta
Publisher: Elsevier Pub. Co
Â© 2011 Elsevier B.V.
Received Day: 2 Month: 6 Year: 2010
Revision Received Day: 13 Month: 7 Year: 2010
Accepted Day: 28 Month: 7 Year: 2010
Print publication date: Month: 1 Year: 2011
Volume: 1808 Issue: 1
First Page: 260 Last Page: 270
PubMed Id: 20691150
Publisher Id: BBAMEM80347
|Amino acid derivatives are substrates or non-transported inhibitors of the amino acid transporter PAT2 (slc36a2)|
|Catriona M.H. Andersona|
|Kelly M. Gatfielda|
|Mark P. Jevonsa|
|David T. Thwaitesa⁎||Email: firstname.lastname@example.org|
aEpithelial Research Group, Institute for Cell & Molecular Biosciences, Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK
bDepartment of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA
|⁎Corresponding author. Tel.: +44 191 222 8559; fax: +44 191 222 7424. email@example.com
The SLC36 (solute carrier 36) family of transporter-related genes consists of four members (SLC36A1–4) in all mammalian genomes investigated thus far [1–3]. The SLC36 transporters, along with the SLC32 and SLC38 families (categorised using the nomenclature of the Human Genome Organisation ), form the β-group cluster of amino acid transporters  and are members of the Amino Acid/Auxin Permease (AAAP) family. The AAAP family is contained within the amino acid/polyamine/organocation (APC) transporter superfamily, as classified using the nomenclature of the Transport Classification Database .
The SLC36A1 gene encodes a H+-coupled amino acid transporter named variously as LYAAT1 or PAT1 . cDNAs for PAT1 have been isolated from rat , mouse , human  and rabbit . When expressed in a heterologous system, PAT1 produces an amino acid transporter that has the functional characteristics of a transport system (named system PAT for Proton-coupled Amino acid Transporter) previously identified at the apical membrane of monolayers of the human intestinal epithelial cell line Caco-2 [12,13]. PAT1 has been identified as the molecular correlate of the imino acid carrier , a transport system identified functionally in rat small intestine as long ago as the 1960s [15–17]. The potential importance of PAT1 in amino acid absorption in the mammalian small intestine is demonstrated by immunolocalisation of PAT1 protein to the luminal surface of Caco-2 cell monolayers, and both human and rat small intestine [7,14]. The substrate specificity of PAT1 has been explored in great detail and PAT1 transports a wide variety of L- and D-amino and imino acids in α-, β- and γ-orientations, and a large number of heterocyclic compounds and orally-delivered drugs related to proline and GABA (for examples see [7,9,13,14,18–23]). Recently PAT1 has been shown to transport the conditionally-essential amino acid taurine  and the photosensitising anti-cancer agent δ-aminolevulinic acid .
In contrast to PAT1, much less is known about the other members of the SLC36 family. SLC36A3/PAT3 and SLC36A4/PAT4 remain orphan transporters with no known function. Based upon homology to PAT1 (for example, human PAT1 and PAT2 (SLC36A2) share 72% identity in amino acid sequence), PAT2 was isolated from mouse , rat  and human . Like PAT1, PAT2 functions as an H+-coupled amino acid transport system when expressed in Xenopus laevis oocytes or human RPE cells. PAT2 has a higher affinity for its substrates, when compared to PAT1, but transports a narrower range of compounds [9,26,27]. Despite the substrate specificity of this transport system being characterised in some detail, the physiological role(s) of the transporter is uncertain as, before isolation of the cDNAs, an endogenous transport system with obvious PAT2-like characteristics had not previously been identified in any tissue. However, a few clues to the likely physiological functions of PAT2 in neuronal and renal tissues have emerged over recent years. Immunolocalisation of PAT2 to the endoplasmic reticulum, recycling endosomes and plasma-membrane of neurones in mouse brain  suggests that PAT2 may be involved in amino acid movement in neuronal tissues. A Na+-independent, relatively low affinity, transporter of glycine, alanine and proline had previously been identified in rat CNS tissues that demonstrates some similarity in function to PAT2 [29,30]. In addition, PAT2 protein (named Tramdorin 1 in the study) was immunolocalised to myelinating Schwann cells suggesting a role in amino acid supply during differentiation . However, the strongest evidence for a physiological role of PAT2 comes from investigations by Bröer and colleagues [32,33]. The SLC36A2 (PAT2) gene was identified as the major gene responsible for iminoglycinuria, a renal defect characterised by reduced reabsorption of glycine, proline and hydroxyproline (Online Mendelian Inheritance in Man, OMIM: 242600). In five pedigrees a single amino acid substitution (G87V) in PAT2 was identified . Expression of the G87V PAT2 mutant in Xenopus oocytes produced a transporter with reduced activity compared to wild-type PAT2 because of decreased affinity for proline and glycine . In a separate pedigree, a splice donor site mutation in the first intron of SLC36A2 was identified. This mutation produced a truncated protein with no function . Thus, a physiological role of PAT2 in the renal proximal tubule is in the reabsorption of glycine, proline and hydroxyproline. This role is emphasised by the recent finding that reduced PAT2 expression in the apical membrane of mouse proximal tubule is responsible in part for the developmental iminoglycinuria observed in neonatal animals .
Although major advances have been made over recent years in our understanding of membrane transporter function in mammalian tissues it is also likely that many unidentified transport systems will play unique physiological roles. These roles can be difficult to define because the function of an individual transporter may be masked, for example, due to coexpression with other transport systems, low level of expression, or limited expression in a sub-population of cells within a mixed tissue. In the case of amino acid transporters, a major difficulty in attributing transport of any individual compound to any single transport system is due to the overlapping substrate specificities and affinities observed between many transporters. The development of a panel of selective substrates or, preferably, non-transported inhibitors will allow discrimination between movements through distinct transport systems. Thus, the objective of this investigation was to identify non-transported inhibitors of the H+-coupled amino acid transporter PAT2. A previous study  emphasised the potential of heterocyclic compounds as lead candidates for this investigation of PAT2 and two key studies using other amino acid transporters [34,35] identified tryptophan analogues as the most likely candidates. To allow identification of transported substrates and non-transported inhibitors, PAT2 was expressed in Xenopus laevis oocytes and transport function characterised using a combination of experimental approaches including radiotracer uptake and competition (cis-inhibition) studies, radiotracer efflux and trans-stimulation, and measurement of substrate-induced positive inward current using the two-electrode voltage-clamp (TEVC) technique.
All amino acids, analogues and derivatives were purchased from Sigma-Aldrich (Poole, UK) except: guvacine and isoguvacine (Tocris, Bristol, UK); α-methyl-D,L-tryptophan, D- and L-pipecolic acids (Bachem, St. Helens, UK); and serotonin (Enzo Life Sciences, Exeter, UK). Radiolabelled amino acids used were: β-[3-3H]alanine (specific activity 50 Ci mmol− 1) and L-[2,3,4,5,6-3H]pipecolic acid (20 Ci mmol− 1) (American Radiolabeled Chemicals, St. Louis, USA); [2-3H]glycine (21 Ci mmol− 1) (GE Healthcare, Little Chalfont, UK); and L-[2,3,4,5-3H]proline (75–85 Ci mmol− 1) (PerkinElmer, Beaconsfield, UK).
Female Xenopus laevis frogs were killed following Schedule 1 methods prior to surgical removal of the ovaries. Oocytes were prepared as described previously [1,27]. Individual stage V/VI oocytes were injected with 50 nl water (control) or cRNA (1 μg μl− 1) synthesised by in vitro transcription of pCRII containing mouse PAT1  or pSPORT1 containing rat PAT2  (there is 85% identity in amino acid sequence between human and mouse PAT1, and 81% identity between human and rat PAT2). Oocytes were maintained in modified Barth's solution (18 °C, 2–7 days) until use.
Oocytes were washed with Na+-free solution (in mM: 100 cholineCl; 2 KCl; 1 CaCl2; 1 MgCl2; 10 MES or 10 HEPES, adjusted to required pH with Tris base). Radiolabel uptake experiments were initiated by replacement of wash solution with 200 μl Na+-free solution (pH 5.5 unless stated otherwise) supplemented with [3H]amino acid (0.01–10 mM, 5 μCi ml− 1). For cis-inhibition experiments, uptake of [3H]amino acid was measured in the absence (control) and presence of competitor compound (0.01–30 mM). Unless stated otherwise, amino acids and derivatives are used routinely in their L-forms. Uptakes were measured over 40 min at 22 °C after which time the oocytes were washed three times with ice-cold Na+-free solution and lysed in 10% SDS before addition of scintillation cocktail (PerkinElmer). For trans-stimulation experiments, oocytes were pre-loaded with proline by microinjection of 50 nl L-[3H]proline (25 mM, 0.1 μCi μl− 1). Assuming an effective oocyte volume of 250 nl , this equates to an intracellular proline concentration of approximately 4 mM. Microinjected oocytes were allowed to recover (15 min) in 200 μl modified Barth's solution (18 °C). Individual oocytes were washed in Na+-free solution (pH 5.5) and incubated (22 °C, 10 min) in 100 μl Na+-free solution (pH 5.5) in the presence or absence of various compounds (all 10 mM). After the 10 min efflux period, the incubation solution was removed for scintillation counting and oocytes washed three times with ice-cold Na+-free solution. Oocytes were lysed in 10% SDS before addition of scintillation cocktail. Sample radioactivity was determined using an LS6500 liquid scintillation counter (Beckman Coulter, High Wycombe, UK).
Two-electrode voltage-clamp (TEVC) experiments were performed as described previously [25,27]. Water or cRNA-injected oocytes were continuously superfused with Na+-free solution (composition as per radiolabel flux experiments) whilst clamped at a membrane potential of − 60 mV. Current changes evoked by exposure (60–120 s) to experimental compounds (0.2–30 mM) were recorded using pClamp software connected to a Geneclamp 500 amplifier and Digidata 1200 (Axon Instruments, Molecular Devices, Sunnyvale, USA) and analysed using Clampfit 8.2 (Axon Instruments). Compound-induced current changes were calculated by subtraction of baseline (average current recorded over 15 s before addition of compound) from the average current recorded over the final 15 s of the exposure. Results are presented as cRNA-specific current (calculated by subtraction of current evoked in water-injected oocytes under identical experimental conditions) and representative trace recordings.
Data are mean ± SEM (n = number of oocytes), except where indicated in the text. Unless stated otherwise, results are expressed as the cRNA-specific response (following subtraction of response in water-injected oocytes under identical experimental conditions). Statistical significance was determined by unpaired or paired, two-tailed Student's t-test or one-way analysis of variance (ANOVA) with Tukey–Kramer multiple comparisons post-testing as appropriate. p < 0.05 was deemed statistically significant. Kinetic parameters were determined by fitting data to Michaelis–Menten kinetics. Statistical and kinetic analyses were performed using GraphPad Prism v.4 (GraphPad Software, San Diego, USA).
The substrate specificity of PAT2 has been characterised to some degree [1,9,26,27]. The major structural features that permit access and translocation of a compound by PAT2 include the presence of a free carboxyl head group, a small apolar side-chain, an amino head group in the α position, limited methylation of the amino group, and the distance between the charged carboxyl and amino head groups [1,9,26,27]. Of the twenty proteinogenic amino acids, glycine, L-alanine and L-proline are transported substrates for PAT2 with the five-membered ring heterocyclic L-proline (Fig. 1) having the highest affinity (Km 0.1–0.2 mM) [1,9,27]. Generally, PAT2 has a preference for L-enantiomers of amino acids although this preference is weaker than that observed in most other mammalian amino acid carriers [9,26,27]. It is possible that the ring structure of proline might allow the substrate to be recognised in a different orientation within the PAT2 binding site or even in distinct orientations (as both an α- and a δ-imino acid) which might help explain why both D-proline and trans-4-hydroxy-L-proline have similar affinities for PAT2 to that observed with L-proline [26,27,37,38]. However, despite this high affinity for prolines, the maximum rate of L-proline transport via PAT2 is less than that observed with glycine [9,26,27]. This suggests that the heterocyclic structures (Fig. 1) are translocated less efficiently than glycine, perhaps due to some sterical hindrance within the transport pocket [26,27].
The lower turnover rate of PAT2 observed at high (mM) concentrations of heterocyclic prolines [9,26,27] suggests that heterocyclic amino acids are potential lead candidates in the identification of PAT2 inhibitors. L-[3H]Proline uptake (over 40 min) under optimal transport conditions (pH 5.5, Na+-free solution) via PAT2 was increased 17-fold above that in water-injected oocytes. PAT2-mediated L-[3H]proline uptake was reduced by the proline derivatives (all 10 mM) L-thiaproline (L-thiazolidine-4-carboxylic acid, TCA), trans-4-hydroxy-L-proline (T4HP), 3,4-dehydro-D,L-proline (DHP), cis-4-hydroxy-D-proline (CHDP), trans-3-hydroxy-L-proline (T3HP) and cis-4-hydroxy-L-proline (CHLP) (Fig. 2A). Modification within the ring structure (replacement of a carbon atom by sulphur in L-thiaproline; inclusion of the double-bond between the β- and γ-carbon atoms in 3,4-dehydro-D,L-proline; or oxidation of the γ-carbon in trans-4-hydroxy-L-proline) was well tolerated although the position and orientation of the hydroxyl group (Fig. 1) in the pyrrolidine ring (as observed in trans-4-hydroxy-L-proline, cis-4-hydroxy-D-proline, trans-3-hydroxy-L-proline and cis-4-hydroxy-L-proline) affected the relative affinity of the compounds for PAT2 (Fig. 2A–B). Trans-4-hydroxy-L-proline, trans-3-hydroxy-L-proline and cis-4-hydroxy-L-proline inhibited PAT2-mediated L-[3H]proline uptake with IC50 values of 0.7 ± 0.2, 13.1 ± 4.2 and > 20 mM, respectively. Competition experiments alone do not discriminate between cis-inhibition by a transported substrate or a non-transported inhibitor. To measure PAT2-mediated transport of these proline derivatives, substrate-induced inward currents were measured by TEVC where the net charge movement across the plasma-membrane is due to H+ influx coupled to amino acid import . The relative inhibitory effect of each proline derivative was matched by its ability to evoke inward current in PAT2-expressing oocytes (Fig. 2C–D) (note that the current induced by trans-4-hydroxy-L-proline (T4HP) was demonstrated previously  to be equivalent to that generated by proline and is not shown here). No amino acid was able to induce current in water-injected oocytes (Fig. 2C). The close correlation between inhibitory potency and induction of current demonstrates that this group of compounds is unlikely to yield a non-transported inhibitor of PAT2.
Previous observations  suggest that the four-membered ring heterocyclic compounds D-cycloserine and L-2-azetidine carboxylate are excellent PAT2 substrates. Thus, to try and identify non-transported inhibitors, we focussed on amino acid analogues containing bulkier ring structures. The six-membered ring cis-3-aminocyclohexanecarboxylic acid is used to selectively discriminate between GABA transport by the four GAT transporters (GAT1–4; SLC6A1, SLC6A13, SLC6A11 and SLC6A12, respectively). Cis-3-aminocyclohexanecarboxylic acid has a higher affinity for GAT1 whereas β-alanine has a preference for GAT3 and 4 . We were unable to obtain cis-3-aminocyclohexanecarboxylic acid for this investigation but we examined a series of related aminocyclohexanecarboxylic acid (ACHC) compounds to determine what effect positioning the amino group outside the cyclic ring structure (Fig. 1) had on PAT2 (in the proline derivatives investigated in Fig. 2 the amino nitrogen is present within the heterocyclic ring). The ACHCs tested (1-aminocyclohexanecarboxylic acid, 1-ACHC; trans-2-aminocyclohexanecarboxylic acid, T2-ACHC; cis-4-aminocyclohexanecarboxylic acid, C4-ACHC; cis-2-aminocyclohexanecarboxylic acid, C2-ACHC) had no significant (p > 0.05) effect on PAT2-mediated L-[3H]proline uptake (Fig. 3A). In addition, all ACHCs investigated failed to induce inward current in PAT2-expressing oocytes (Fig. 3B–C). The reason for the lack of interaction of these compounds with PAT2 is not known but it is possible that the extra-cyclic nature of the amino nitrogen (Fig. 1) will allow the six-membered ring to be recognised as a bulky side-chain which, like bulky side-chain containing α-amino acids, is not tolerated by PAT2.
Other heterocyclic GABA-related compounds are used to selectively inhibit GAT transporters (such as guvacine) or as agonists for GABAA receptors (such as isoguvacine) [39–41]. In contrast to the ACHCs (Fig. 3), the amino nitrogen in guvacine and isoguvacine is contained within the heterocyclic ring (which also contains an unsaturated double-bond) (Fig. 1). Guvacine (Guv) and isoguvacine (Isoguv) (both 10 mM) significantly (p < 0.001) inhibited L-[3H]proline uptake (Fig. 4A) and the level of inhibition was consistent with the ability to induce inward current in PAT2-expressing oocytes (Fig. 4B–C) suggesting that both compounds are low affinity transported substrates of PAT2.
The six-membered heterocyclic ring (saturated) piperidine carboxylates pipecolic acid, nipecotic acid (a GAT transport inhibitor with a similar structure to guvacine) and isonipecotic acid (a GABAA receptor agonist with a similar structure to isoguvacine) differ from each other by the distance between the amino and carboxyl groups (Fig. 1). Our previous investigation demonstrated that isonipecotic acid, nipecotic acid, and D- and L-pipecolic acids all inhibited PAT2-mediated L-[3H]proline uptake  with L-pipecolic acid being the most potent inhibitor (IC50 1.2 mM). However, all four compounds were relatively poor at inducing inward currents via PAT2 . This observation suggested that these heterocyclic compounds were only weakly translocated substrates for PAT2 and that they could prove useful lead compounds in the development of PAT2 inhibitors.
When glycine in the superfusate is increased from a sub-saturating (0.3 mM) to a saturating (10 mM) concentration (Km for glycine 0.5–0.7 mM) [1,9] the increase in glycine-induced current (p < 0.01) represents an increase from sub-maximal to maximal PAT2 transport (Fig. 5A and C). In contrast, when the total amino acid concentration is increased from the sub-saturating 0.3 mM concentration of glycine to the saturating concentration of L-pipecolic acid (L-Pip) (10 mM L-pipecolic acid plus 0.3 mM glycine) a decrease in the amino acid-induced current is observed (Fig. 5A and C). The current induced by 10 mM L-pipecolic acid is significantly smaller (p < 0.001) than that observed in the presence of 10 mM glycine (Fig. 5A). Similar observations were made with D-pipecolic (D-Pip), nipecotic (Nip) and isonipecotic (Isonip) acids (Fig. 5B–C). The apparent inhibitory effect (presumably due to a reduced rate of translocation) of L-pipecolic acid is confirmed in Fig. 5D–E where the current induced by 10 mM L-pipecolic acid alone is significantly less (p < 0.01) than that observed following exposure to 3 mM glycine. In addition, the current induced by the combination of saturating concentrations of L-pipecolic acid and glycine (10 and 3 mM, respectively) is significantly less (p < 0.05) than that induced by 3 mM glycine alone (Fig. 5D–E). In this particular group of compounds, the distance between polar head groups appears important as the greatest restriction to movement through the transporter occurs with L-pipecolic acid whereas elongation of the distance between carboxyl and amino groups, as observed in isonipecotic acid (Fig. 1), improves translocation (as measured by the isonipecotic acid-evoked current) (Fig. 5B–C).
It is possible that, rather than a slow translocation, the low level of current observed in the presence of L-pipecolic acid is due to a dissociation of amino acid and proton transport via PAT2 such that L-pipecolic acid is transported in a partially uncoupled mode. However, that does not appear to be the case as PAT2-mediated L-[3H]pipecolic acid uptake is much reduced (p < 0.001) compared to [3H]glycine due to a reduction in Vmax from 934 ± 22 to 224 ± 19 pmol oocyte− 1 (40 min)− 1 (Fig. 5F). Thus, the levels of uptake of radiotracer forms of L-pipecolic acid and glycine are comparable to the relative levels of current induced by the two compounds demonstrating that there is no uncoupling of PAT2 transport. Finally, the low level of L-[3H]pipecolic acid uptake was not due to altered pH-dependence of the transporter as the uptake of L-[3H]pipecolic acid and [3H]glycine had an identical pattern over the pH range (5.5–8.0) investigated (Fig. 5G). The weakly transported nature of L-pipecolic acid via PAT2 demonstrates that it will have limited utility as a tool to provide unequivocal evidence for PAT2 function in native tissues. However, it should be useful when used in conjunction with other substrates and inhibitors and it is a good lead structure to aid the design of novel PAT2 inhibitors. The handling of L-pipecolic acid also distinguishes between PAT1 and PAT2 [14,27]. In PAT1, the levels of L-pipecolic acid translocation and competition are comparable, whereas in PAT2 it is a more effective blocker than transported substrate.
Recently, certain members of a separate group of heterocyclic amino acids, including the aromatic amino acid tryptophan and its derivatives (all of which contain an indole scaffold) (Fig. 1), have been identified as non-transported inhibitors of the amino acid transporters PAT1 (SLC36A1) and ATB0,+ (SLC6A14), respectively [34,35]. This group of compounds was investigated to determine their effects on PAT2 function. L-[3H]Proline uptake was inhibited significantly (p < 0.001) by 5-hydroxy-L-tryptophan (OH-Trp), α-methyl-D,L-tryptophan (Me-Trp), L-tryptophan (L-Trp), 1-methyl-L-tryptophan (1-Me-L-Trp) and indole-3-propionic acid (3-IPA) (all 10 mM) whereas the D-enantiomers D-tryptophan (D-Trp) and 1-methyl-D-tryptophan (1-Me-D-Trp) were without effect (p > 0.05) (Fig. 6A). The presence of the carboxyl group seems important in PAT2 binding as the decarboxylated amines tryptamine (Trypt) and serotonin (5-hydroxytryptamine, 5-HT) (both 10 mM) were without effect (p > 0.05) on L-[3H]proline uptake (Fig. 6A) whereas they interact with PAT1 with reasonable affinity . Methylation of the α carbon atom (α-methyl-D,L-tryptophan) or nitrogen within the indole ring structure (1-methyl-L-tryptophan) (Fig. 1) was tolerated. The inhibition observed with indole-3-propionic acid suggests that the amino nitrogen on the α carbon atom is not a prerequisite for PAT2 binding.
The greatest level of inhibition of PAT2-mediated amino acid uptake was observed with the tryptophan derivatives 5-hydroxy-L-tryptophan and α-methyl-D,L-tryptophan and their interaction with PAT2 was investigated further. 5-Hydroxy-L-tryptophan and α-methyl-D,L-tryptophan inhibited L-[3H]proline uptake in a concentration-dependent manner with IC50 values of 1.6 ± 0.4 and 3.5 ± 1.5 mM, respectively (Fig. 6B). Neither 5-hydroxy-L-tryptophan nor α-methyl-D,L-tryptophan (both 20 mM) alone were able to elicit significant (p > 0.05 versus water-injected oocytes) current in PAT2-expressing oocytes (Fig. 6C–D). However, both 5-hydroxy-L-tryptophan and α-methyl-D,L-tryptophan (both 20 mM) caused significant (p < 0.001) reductions in current evoked by 0.2 mM L-proline (Fig. 6C and E). α-Methyl-D,L-tryptophan inhibited the L-proline-induced current with an IC50 of 2.7 ± 0.1 mM (Fig. 6F).
A comparison of the effects of 5-hydroxy-L-tryptophan and α-methyl-D,L-tryptophan on amino acid transport by PAT1 and PAT2 demonstrates that both tryptophan derivatives (10 mM) inhibit PAT2 with similar efficacy whereas 5-hydroxy-L-tryptophan causes a significantly greater (p < 0.001) inhibition of amino acid uptake via PAT1 than α-methyl-D,L-tryptophan (Fig. 7A). Extension of this comparison to include all of the tryptophan derivatives used in Fig. 6 allows the demonstration of a clear difference in the inhibition profile observed against amino acid uptake via PAT1 and PAT2 (Fig. 7B).
The ability of 5-hydroxy-L-tryptophan and α-methyl-D,L-tryptophan to inhibit PAT2-mediated amino acid transport and current, combined with the lack of inward current observed, suggests either that they represent non-transported blockers of PAT2 function or that they are PAT2 substrates transported in an electroneutral manner.
As suggested above, a potential limitation of measurement of substrate-induced currents by the TEVC technique is that electroneutral movement of compounds through the carrier cannot be detected. This has been demonstrated previously where H+-coupled short-chain fatty acid transport via both PAT1 and PAT2 occurs in an electroneutral fashion . To address this issue, we determined the ability of various compounds to trans-stimulate L-[3H]proline efflux from oocytes pre-loaded by microinjection. In the absence of external amino acids, there was no significant (p > 0.05) difference in L-[3H]proline efflux from PAT2-expressing (22 ± 3 (n = 50) pmol oocyte− 1 (10 min)− 1) or water-injected (21 ± 2 (n = 50) pmol oocyte− 1 (10 min)− 1) oocytes (Fig. 8A). However, when the prototypical PAT2 substrate glycine (10 mM) was added to the extracellular compartment, a significant increase (p < 0.001) in L-[3H]proline efflux was observed from PAT2 (272 ± 10 (n = 50) pmol oocyte− 1 (10 min)− 1) but not water-injected (19 ± 2 (n = 50) pmol oocyte− 1 (10 min)− 1) oocytes, which represents a 14-fold increase in efflux. An example is shown in Fig. 8A where the presence of extracellular glycine (10 mM) is shown to increase L-[3H]proline efflux whereas 5-hydroxy-L-tryptophan and α-methyl-D,L-tryptophan (both 10 mM) have no effect (p > 0.05 versus water-injected oocytes). These data are consistent with the inhibitory effects of 5-hydroxy-L-tryptophan and α-methyl-D,L-tryptophan on amino acid-induced current via PAT2 (Section 3.4) being due to the two compounds acting as non-transported blockers of PAT2. Fig. 8B demonstrates that the ability of a compound in the extracellular compartment to stimulate L-[3H]proline efflux via PAT2 appears related to its ability to undergo PAT2-mediated translocation. Thus, the PAT2 substrates glycine (Gly), L-alanine (Ala) and sarcosine (Sar) all trans-stimulate L-[3H]proline efflux (Fig. 8B) whereas glutamic acid (Glu), which is excluded from PAT2, has no effect (Fig. 8B). The weakly transported heterocyclic compounds stimulate relatively low levels of efflux with isonipecotic acid (Isonip) being more effective than L-pipecolic acid (L-Pip). A direct relationship between the relative ability of compounds to cis-inhibit PAT2-mediated amino acid uptake and to trans-stimulate PAT2-mediated amino acid efflux can be observed in Fig. 8C. A deviation from the linear relationship, as observed with both 5-hydroxy-L-tryptophan and α-methyl-D,L-tryptophan, provides evidence for the inhibitory effects being due to the compounds acting as transport blockers rather than transported substrates.
A number of proline, GABA and tryptophan derivatives were examined to determine if they function either as transported substrates or non-transported inhibitors of the H+-coupled amino acid transporter PAT2. In general, the proline analogues were transported substrates with varying affinity for the transporter whereas the GABA analogues, in particular L-pipecolic acid, appear to be translocated relatively slowly. In contrast, both 5-hydroxy-L-tryptophan and α-methyl-D,L-tryptophan function as non-transported inhibitors of PAT2. Although the affinity of both compounds is relatively low, compared to the high affinity (IC50 approximately 250 μM) observed for the effect of α-methyl-D,L-tryptophan on amino acid transport via ATB0,+, they are likely to prove highly useful experimental tools in the further investigation of the physiological roles of PAT2. Our knowledge of the physiological importance of PAT2 is limited although it seems likely to have roles in amino acid transport in both renal and neuronal tissues [26–28,31,32]. In addition, a recent study examining changes in gene expression in horses during implantation and early pregnancy demonstrates that the SLC36A2 gene is highly upregulated in uterine tissues, perhaps reflecting the increased nutrient demands of the developing conceptus . Understanding the substrate/inhibitor profile of a particular amino acid transporter has a number of potential uses in pathophysiological conditions as amino acid transporters can be utilised to mediate uptake of substrates that will alter cellular function or as a mechanism to deprive cells of essential nutrients . Finally, the availability of non-transported inhibitors has utility in crystallographic studies, where the transport inhibitor can be used to trap a transporter protein in the open-to-out conformation, as observed with the leucine transporter LeuT .
|Chen Z.,Kennedy D.J.,Wake K.A.,Zhuang L.,Ganapathy V.,Thwaites D.T.. Structure, tissue expression pattern, and function of the amino acid transporter rat PAT2Biochem. Biophys. Res. Commun.304Year: 200374775412727219|
|Boll M.,Foltz M.,Rubio-Aliaga I.,Daniel H.. A cluster of proton/amino acid transporter genes in the human and mouse genomesGenomics82Year: 2003475612809675|
|Bermingham J.R.,Pennington J.. Organization and expression of the SLC36 cluster of amino acid transporter genesMamm. Genome14Year: 200411412515058382|
|Hediger M.A.,Romero M.F.,Peng J.B.,Rolfs A.,Takanaga H.,Bruford E.A.. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsPflügers Arch.447Year: 2004465468|
|Fredriksson R.,Nordström K.J.V.,Stephansson O.,Hägglund M.G.A.,Schiöth HB H.B.. The solute carrier (SLC) complement of the human genome: phylogenetic classification reveals four major familiesFEBS Lett.582Year: 20083811381618948099|
|Saier M.H. Jr.,Tran C.V.,Barabote R.D.. TCDB: the Transporter Classification Database for membrane transport protein analyses and informationNucleic Acids Res.34Year: 2006D181D186 (Database issue). 16381841|
|Thwaites D.T.,Anderson C.M.H.. Deciphering the mechanisms of intestinal imino (and amino) acid transport: the redemption of SLC36A1Biochim. Biophys. Acta1768Year: 200717919717123464|
|Sagné C.,Agulhon C.,Ravassard P.,Darmon M.,Hamon M.,El Mestikawy S.,Gasnier B.,Giros B.. Identification and characterization of a lysosomal transporter for small neutral amino acidsProc. Natl. Acad. Sci. U. S. A.98Year: 20017206721111390972|
|Boll M.,Foltz M.,Rubio-Aliaga I.,Kottra G.,Daniel H.. Functional characterization of two novel mammalian electrogenic proton-dependent amino acid cotransportersJ. Biol. Chem.277Year: 2002229662297311959859|
|Chen Z.,Fei Y.J.,Anderson C.M.H.,Wake K.A.,Miyauchi S.,Huang W.,Thwaites D.T.,Ganapathy V.. Structure, function and immunolocalization of a proton-coupled amino acid transporter (hPAT1) in the human intestinal cell line Caco-2J. Physiol.546Year: 200334936112527723|
|Miyauchi S.,Abbot E.L.,Zhuang L.,Subramanian R.,Ganapathy V.,Thwaites D.T.. Isolation and function of the amino acid transporter PAT1 (slc36a1) from rabbit and discrimination between transport via PAT1 and system IMINO in renal brush-border membrane vesiclesMol. Membr. Biol.22Year: 200554955916373326|
|Thwaites D.T.,McEwan G.T.A.,Brown C.D.A.,Hirst B.H.,Simmons N.L.. Na+-independent, H+-coupled transepithelial β-alanine absorption by human intestinal Caco-2 cell monolayersJ. Biol. Chem.268Year: 199318438184418395502|
|Thwaites D.T.,McEwan G.T.A.,Simmons N.L.. The role of the proton electrochemical gradient in the transepithelial absorption of amino acids by human intestinal Caco-2 cell monolayersJ. Membr. Biol.145Year: 19952452567563025|
|Anderson C.M.H.,Grenade D.S.,Boll M.,Foltz M.,Wake K.A.,Kennedy D.J.,Munck L.K.,Miyauchi S.,Taylor P.M.,Campbell F.C.,Munck B.G.,Daniel H.,Ganapathy V.,Thwaites D.T.. H+/amino acid transporter 1 (PAT1) is the imino acid carrier: an intestinal nutrient/drug transporter in human and ratGastroenterology127Year: 20041410142215521011|
|Daniels V.G.,Dawson A.G.,Newey H.,Smyth D.H.. Effect of carbon chain length and amino group position on neutral amino acid transport systems in rat small intestineBiochim. Biophys. Acta173Year: 19695755775769651|
|Thompson E.,Levin R.J.,Jackson M.J.. The stimulating effect of low pH on the amino acid transferring systems of the small intestineBiochim. Biophys. Acta196Year: 19701201225412245|
|Munck B.G.,Munck L.K.,Rasmussen S.N.,Polache A.. Specificity of the imino acid carrier in rat small intestineAm. J. Physiol.266Year: 1994R1154R11618184957|
|Thwaites D.T.,Basterfield L.,McCleave P.M.J.,Carter S.M.,Simmons N.L.. Gamma-aminobutyric acid (GABA) transport across human intestinal epithelial (Caco-2) cell monolayersBr. J. Pharmacol.129Year: 200045746410711343|
|Boll M.,Foltz M.,Anderson C.M.H.,Oechsler C.,Kottra G.,Thwaites D.T.,Daniel H.. Substrate recognition by the mammalian proton-dependent amino acid transporter PAT1Mol. Membr. Biol.20Year: 200326126912893527|
|Metzner L.,Neubert K.,Brandsch M.. Substrate specificity of the amino acid transporter PAT1Amino Acids31Year: 200611111716699824|
|Abbot E.L.,Grenade D.S.,Kennedy D.J.,Gatfield K.M.,Thwaites D.T.. Vigabatrin transport across the human intestinal epithelial (Caco-2) brush-border membrane is via the H+-coupled amino acid transporter hPAT1Br. J. Pharmacol.147Year: 200629830616331283|
|Metzner L.,Kalbitz J.,Brandsch M.. Transport of pharmacologically active proline derivatives by the human proton-coupled amino acid transporter hPAT1J. Pharmacol. Exp. Ther.309Year: 2004283514718599|
|Larsen M.,Holm M.R.,Jensen K.G.,Brodin B.,Nielsen C.U.. Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophanBr. J. Pharmacol.157Year: 20091380138919594759|
|Anderson C.M.H.,Howard A.,Walters J.R.F.,Ganapathy V.,Thwaites D.T.. Taurine uptake across the human intestinal brush-border membrane is via two transporters: H+-coupled PAT1 (SLC36A1) and Na+- and Cl−-dependent TauT (SLC6A6)J. Physiol.587Year: 200973174419074966|
|Anderson C.M.H.,Jevons M.,Thangaraju M.,Edwards N.,Conlon N.J.,Woods S.,Ganapathy V.,Thwaites D.T.. Transport of the photodynamic therapy agent 5-aminolevulinic acid by distinct H+-coupled nutrient carriers coexpressed in the small intestineJ. Pharmacol. Exp. Ther.332Year: 201022022819789362|
|Foltz M.,Oechsler C.,Boll M.,Kottra G.,Daniel H.. Substrate specificity and transport mode of the proton-dependent amino acid transporter mPAT2Eur. J. Biochem.271Year: 20043340334715291811|
|Kennedy D.J.,Gatfield K.M.,Winpenny J.P.,Ganapathy V.,Thwaites D.T.. Substrate specificity and functional characterisation of the H+/amino acid transporter rat PAT2 (Slc36a2)Br. J. Pharmacol.144Year: 2005284115644866|
|Rubio-Aliaga I.,Boll M.,Vogt-Weisenhorn D.M.,Foltz M.,Kottra G.,Daniel H.. The proton/amino acid cotransporter PAT2 is expressed in neurons with a different subcellular localization than its paralog PAT1J. Biol. Chem.279Year: 20042754276014600155|
|Johnston G.A.R.,Iversen L.L.. Glycine uptake in rat central nervous system slices and homogenates: evidence for different uptake systems in spinal cord and cerebral cortexJ. Neurochem.18Year: 1971195119614399087|
|Bennett J.P.,Mulder A.H.,Snyder S.H.. Neurochemical correlates of synaptically active amino acidsLife Sci.15Year: 1974104510564157276|
|Bermingham J.R.,Shumas S.,Whisenhunt T.,Sirkowski E.E.,O'Connell S.,Scherrer S.S.,Rosenfeld M.G.. Identification of genes that are downregulated in the absence of the POU domain transcription factor pou3f1 (Oct-6, Tst-1, SCIP) in sciatic nerveJ. Neurosci.22Year: 2002102171023112451123|
|Bröer S.,Bailey C.G.,Kowalczuk S.,Ng C.,Vanslambrouck J.M.,Rodgers H.,Auray-Blais C.,Cavanaugh J.A.,Bröer A.,Rasko J.E.. Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transportersJ. Clin. Invest.118Year: 20083881389219033659|
|Vanslambrouck J.M.,Bröer A.,Thavyogarajah T.,Holst J.,Bailey C.G.,Bröer S.,Rasko J.E.. Renal imino acid and glycine transport system ontogeny and involvement in developmental iminoglycinuriaBiochem. J.428Year: 201039740720377526|
|Metzner L.,Kottra G.,Neubert K.,Daniel H.,Brandsch M.. Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1FASEB J.19Year: 20051468147316126914|
|Karunakaran S.,Umapathy N.S.,Thangaraju M.,Hatanaka T.,Itagaki S.,Munn D.H.,Prasad P.D.,Ganapathy V.. Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapyBiochem. J.414Year: 200834335518522536|
|You G.,Smith C.P.,Kanai Y.,Lee W.-S.,Stelzner M.,Hediger M.A.. Cloning and characterization of the vasopressin-regulated urea transporterNature365Year: 19938448478413669|
|Christensen H.N.,Greene A.A.,Kakuda D.K.,MacLeod C.L.. Special transport and neurological significance of two amino acids in a configuration conventionally designated as DJ. Exp. Biol.196Year: 19942973057823029|
|Stevens B.R.,Wright E.M.. Substrate specificity of the intestinal brush-border proline/sodium (IMINO) transporterJ. Membr. Biol.87Year: 198527344057242|
|Madsen K.K.,White H.S.,Schousboe A.. Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugsPharmacol. Ther.125Year: 201039440120026354|
|Krogsgaard-Larsen P.,Falch E.,Larsson O.M.,Schousboe A.. GABA uptake inhibitors: relevance to antiepileptic drug researchEpilepsy Res.1Year: 198777932973980|
|Mortensen M.,Kristiansen U.,Ebert B.,Frølund B.,Krogsgaard-Larsen P.,Smart T.G.. Activation of single heteromeric GABA(A) receptor ion channels by full and partial agonistsJ. Physiol.557Year: 200438941314990676|
|Foltz M.,Boll M.,Raschka L.,Kottra G.,Daniel H.. A novel bifunctionality: PAT1 and PAT2 mediate electrogenic proton/amino acid and electroneutral proton/fatty acid symportFASEB J.18Year: 20041758176015345686|
|Klein C.,Scoggin K.E.,Ealy A.D.,Troedsson M.H.. Transcriptional profiling of equine endometrium during the time of maternal recognition of pregnancyBiol. Reprod.83Year: 201010211320335638|
|Singh S.K.,Piscitelli C.L.,Yamashita A.,Gouaux E.. A competitive inhibitor traps LeuT in an open-to-out confirmationScience322Year: 20081655166119074341|
This work was supported by the Wellcome Trust (grant number: 078640/Z/05/Z), BBSRC (grant number: 13/D17277), and MRC (grant number: G9801704). NE, KMG and MPJ were supported by BBSRC PhD studentships. The mouse PAT1 cDNA was a kind gift from Dr. M. Boll (Technical University of Munich, Germany). We acknowledge gratefully the excellent technical support of Mrs. Lisa Burdis.
Keywords: Abbreviations 1-ACHC, 1-aminocyclohexanecarboxylic acid, C2-ACHC, cis-2-aminocyclohexanecarboxylic acid, C4-ACHC, cis-4-aminocyclohexanecarboxylic acid, CHDP, cis-4-hydroxy-D-proline, CHLP, cis-4-hydroxy-L-proline, DHP, 3,4-dehydro-D,L-proline, Guv, guvacine, 3-IPA, indole-3-propionic acid, Isoguv, isoguvacine, Isonip, isonipecotic acid, Me-Trp, α-methyl-D,L-tryptophan, 1-Me-D-Trp, 1-methyl-D-tryptophan, 1-Me-L-Trp, 1-methyl-L-tryptophan, Nip, nipecotic acid, OH-Trp, 5-hydroxy-L-tryptophan, D-Pip, D-pipecolic acid, L-Pip, L-pipecolic acid, Sar, sarcosine, SLC, solute carrier family, T2-ACHC, trans-2-aminocyclohexanecarboxylic acid, TCA, L-thiaproline (L-thiazolidine-4-carboxylic acid), T4HP, trans-4-hydroxy-L-proline, T3HP, trans-3-hydroxy-L-proline, Trypt, tryptamine.
Keywords: Keywords PAT2, Amino acid transport, SLC36, PAT1, Tryptophan, Inhibitor.
Previous Document: The multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective extraction ...
Next Document: A novel class of photo-triggerable liposomes containing DPPC:DC(8,9)PC as vehicles for delivery of d...